

Bristol Myers Squibb | Board of Directors

Giovanni Caforio, M.D.

Board Chair and Chief Executive Officer,
Bristol Myers Squibb

Theodore R. Samuels

Lead Independent Director, Bristol Myers Squibb;
Retired President of Capital Guardian
Trust Company
(a, b)

Peter J. Arduini

President and Chief Executive Officer,
GE Healthcare
(c, d)

Julia A. Haller, M.D.

Ophthalmologist-in-Chief, Wills Eye Hospital
(b, d)

Manuel Hidalgo Medina, M.D., Ph.D.

Chief, Division of Hematology and Medical
Oncology, Weill Cornell Medicine and New York-
Presbyterian/Weill Cornell Medical Center
(d)

Paula A. Price

Former Executive Vice President
and Chief Financial Officer, Macy's Inc.
(a, b)

Derica W. Rice

Former Executive Vice President, CVS Health
and President, Pharmacy Benefits Business, CVS
Caremark. Former Executive Vice President and
Chief Financial Officer, Eli Lilly Company (a, c)

Gerald L. Storch

Chief Executive Officer, Storch Advisors.
Former Chief Executive Officer of Hudson's
Bay Company
(b, c)

Karen H. Vousden, Ph.D.

Chief Scientist, Cancer Research UK and
Senior Group Leader, The Francis Crick Institute
(c, d)

Phyllis R. Yale

Advisory Partner, Bain & Company
(a, b)

Members of the Board of Directors and Committee memberships as of March 10, 2022

(a) Audit Committee

(b) Committee on Directors and Corporate Governance

(c) Compensation and Management Development Committee

(d) Science and Technology Committee

Bristol Myers Squibb | Leadership Team

Giovanni Caforio, M.D.

Board Chair and
Chief Executive Officer

Chris Boerner, Ph.D.

Executive Vice President,
Chief Commercialization Officer

David Elkins

Executive Vice President,
Chief Financial Officer

Pamela Fisher

Vice President,
Chief Diversity and Inclusion Officer

Cari Gallman

Senior Vice President,
Chief Compliance and Ethics Officer

Samit Hirawat, M.D.

Executive Vice President,
Chief Medical Officer,
Global Drug Development

Sandra Leung

Executive Vice President,
General Counsel

Greg Meyers

Executive Vice President,
Chief Digital and Technology Officer

Elizabeth A. Mily

Executive Vice President,
Strategy and Business Development

Ann M. Powell

Executive Vice President,
Chief Human Resources Officer

Karin Shanahan

Executive Vice President,
Global Product Development and Supply

Catalina Vargas

Chief of Staff to the Chief Executive Officer

Rupert Vessey, M.A., B.M., B.Ch., F.R.C.P., D.Phil.

Executive Vice President and President,
Research and Early Development

Estelle Vester-Blokland, M.D.

Senior Vice President,
Global Medical Affairs

Michelle Weese

Executive Vice President,
Corporate Affairs

BRISTOL MYERS SQUIBB Stockholder Information

Common Stock

Ticker symbol: BMY
New York Stock Exchange

Contingent Value Right

Ticker symbol: CELG-RT
New York Stock Exchange

Stockholder Services

All inquiries concerning stockholder accounts and stock transfer matters – including address changes, the elimination of duplicate mailings and the Shareowner Services Plus PlanSM – should be directed to the Company's Transfer Agent and Registrar:

EQ Shareowner Services
1110 Centre Pointe Curve, Suite 101
Mendota Heights, MN 55120-4100
www.shareowneronline.com
855-598-5485 (within the U.S.)
651-450-4064 (outside the U.S.)

A telecommunications relay service should be used by the hearing impaired when calling the telephone numbers above.

Shareowner Services Plus PlanSM

The Shareowner Services Plus PlanSM is designed for long-term investors who wish to build share ownership in the Company's common stock over time. You can participate in the plan if you are a registered holder of the Company's common stock. If you do not own the Company's common stock, you can become a participant by making your initial purchase through the plan. The plan features dividend reinvestment, optional cash purchase, share safekeeping, and share sales and transfers. Bristol-Myers Squibb Company has appointed EQ Shareowner Services as Administrator for the plan. The plan is not sponsored or administered by Bristol-Myers Squibb Company.

Form 10-K

For a free copy of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, contact:

Corporate Secretary Bristol-Myers Squibb Company
430 E. 29th Street, 14FL
New York, NY 10016

The Form 10-K is also available at investor.bms.com

The most recent certifications by the Company's chief executive officer and chief financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 are filed as exhibits to the Company's Form 10-K. The Company has also filed with the New York Stock Exchange the most recent Annual CEO Certification as required by Section 303A.12(a) of the New York Stock Exchange Listed Company Manual.

Additional Information

Information on the following subjects is available at www.bms.com:

- Bristol Myers Squibb Foundation
- Clinical Trials
- Compliance and Ethics
- Diversity and Workforce Statistics
- Patient Assistance Programs
- Policy and Advocacy Engagement and Political Contributions
- Sustainability/Environmental Programs

This Annual Report contains certain forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations and involve inherent risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations. Please see page 32 in the Financial Review for a discussion and description of these risks and uncertainties. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Product Names and Company Programs

Global products and company program names appearing throughout in italics are referred to herein by their registered and approved U.S. trademarks, unless specifically noted otherwise.

Abilify is a trademark of Otsuka Pharmaceutical Co., Ltd.

Atripla is a trademark of Gilead Sciences, Inc.

Byetta is a trademark of Amylin Pharmaceuticals, LLC

CABOMETYX is a trademark of Exelixis, Inc.

Erbix is a trademark of ImClone LLC

Farxiga and *Onglyza* are trademarks of AstraZeneca AB

Keytruda is a trademark of Merck Sharp & Dohme Corp.

Otezla is a trademark of Amgen Inc.

Tecentriq is a trademark of Genentech, Inc.

Yescarta is a trademark of Kite Pharma, Inc.

Brand names of products that are in all italicized letters, without an asterisk, are registered trademarks of Bristol Myers Squibb and/or one of its subsidiaries.